-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
surgery
-
Bronchoscopic Ablation: A Small Step for Heat Therapy, a Giant Leap for Lung Cancer
Surgery has long been the gold standard for diagnosis and management of early-stage operable lung cancer. For patients with inoperable disease or more extensive disease, however, alternative approaches are emerging. For example, there are ample data to support stereotactic body radiation therapy as an alternative treatment.1 Percutaneous ablation, however, despite being available for 2 decades, is…
-
Transbronchial Microwave Ablation of Malignant Lung Nodules: Outcomes, Challenges, and Perspective
With increasing availability of CT scans and strong evidence for the utility of low-dose CT screening in high-risk populations,1 an increasing number of small lung nodules are being incidentally discovered. Many are small, subsolid, and may harbor premalignant or early-stage tumors. Local treatment of early primary lung cancers and lung oligometastases is gaining popularity, especially…
-
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis, platinum doublet chemotherapy, the current standard of care following complete resection of stage II/III NSCLC, only improved 5-year survival by 5.4%.1 “There is clearly unmet…
-
Sublobar Resections for Early Lung Cancer
By Tetsuya Mitsudomi, MD Posted: April 16, 2020 The general principle of surgery for cancer of any organ is to remove the entire tumor with adequate margins of normal tissue along with regional lymph nodes that may have the potential for metastatic spread, even if preoperative imaging studies do not indicate any signs of metastases.…
-
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field of lung cancer research. Treatment progress gained momentum and finally reached a tipping point in the mid-2010s, with the number of advances over the last…
-
Smoking Cessation Prior to Lung Cancer Surgery
By Jessica Donington, MD, MSCR Posted: November 12, 2019 Dr. Jessica Donington Approximately 80% to 85% of patients undergoing lung cancer resections have a smoking history, and 20% are active smokers. Never smokers have improved short- and long-term outcomes following lung resection compared to those who have smoked. The value of smoking cessation prior to or…